According to filings with the U.S. Securities and Exchange Commission, OnKure is raising $60,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Anthony Piscopio played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OnKure
OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. As a team of veterans with a track record of successful drug discovery and development, we are leveraging our proven structure-based drug design approach to create a robust pipeline of drug candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing its lead clinical candidate OKI-179, an oral Class I HDAC inhibitor, for the treatment of both hematological and solid tumors, as well as exploring other validated oncology targets and pathways. In the evolving landscape of precision oncology, our successful tumor-agnostic approach is key to discovering new treatments for cancer patients with unmet medical needs.

To learn more about OnKure, visit http://onkuretherapeutics.com/

Contact:
Anthony Piscopio, Chief Executive Officer
720-307-2892
https://www.linkedin.com/in/tony-piscopio-93a2338/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.